<DOC>
	<DOCNO>NCT01106677</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety canagliflozin compare sitagliptin placebo patient type 2 diabetes mellitus receive treatment metformin monotherapy ( i.e. , treatment single drug ) inadequate glycemic ( blood sugar ) control .</brief_summary>
	<brief_title>The CANTATA-D Trial ( CANagliflozin Treatment Trial Analysis - DPP-4 Inhibitor Comparator Trial )</brief_title>
	<detailed_description>Canagliflozin drug test see may useful treat patient diagnose type 2 diabetes mellitus ( T2DM ) . This randomize ( study drug assign chance ) , double-blind ( neither patient study doctor know identity assign study drug ) , placebo- active-controlled , parallel-group , 4-arm ( 4 treatment group ) multicenter study determine efficacy , safety , tolerability canagliflozin ( 100 mg 300 mg ) compare placebo ( capsule look like treatment real medicine ) active-control ( sitagliptin 100 mg , antihyperglycemic agent ) patient T2DM achieve adequate response current antihyperglycemic therapy metformin Immediate Release ( IR ) control diabetes . Approximately 1,260 patient T2DM receive treatment metformin IR inadequate glycemic ( blood sugar ) receive once-daily treatment canagliflozin ( 100 mg 300 mg ) , sitagliptin 100 mg , placebo capsule 26 week ( Period I ) follow another 26-weeks patient treat canagliflozin ( 100 mg 300 mg ) sitagliptin 100 mg continue treatment additional 26 week patient treat placebo switch active double-blind treatment sitagliptin 100 mg capsule administer once-daily 26 week ( Period II ) . In addition , patient take protocol specify stable dos metformin IR along assign study drug duration study . Patients participate study approximately 59 71 week . During study , patient 's fasting blood sugar remain high despite treatment study drug , metformin IR , reinforcement diet exercise , patient receive treatment glimepiride ( rescue therapy ) consistent local prescribe information . During treatment , patient monitor safety review adverse event , result laboratory test , 12-lead electrocardiogram ( ECGs ) , vital sign measurement , body weight , physical examination , self-monitored blood glucose ( SMGB ) measurement . The primary outcome measure study assess effect canagliflozin relative placebo hemoglobin A1c ( HbA1c ) 26 week treatment . Study drug take orally ( mouth ) daily first meal day unless otherwise specify . Patients take single-blind placebo 2 week randomization . After randomization , patient study take double-blind canagliflozin ( 100 mg 300 mg ) sitagliptin 100 mg 52 week OR placebo 26 week switch double-blind treatment sitaliptin 100 mg 26 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>All patient must diagnosis T2DM currently treat metformin IR Patients study must HbA1c &gt; =7 &lt; =10.5 % Patients must fast plasma glucose ( FPG ) &lt; 270 mg/dL ( 15 mmol/L ) History diabetic ketoacidosis , type 1 diabetes mellitus ( T1DM ) , pancreas beta cell transplantation , diabetes secondary pancreatitis pancreatectomy , severe hypoglycemic episode within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>Januvia</keyword>
	<keyword>Metformin Immediate Release ( IR )</keyword>
	<keyword>Hemoglobin A1c</keyword>
</DOC>